Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine

Jonathan B. Rosenberg, Bishnu P. De, Martin J. Hicks, Kim D. Janda, Stephen M. Kaminsky, Stefan Worgall, Ronald Crystal

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Despite antismoking campaigns, cigarette smoking remains a pervasive addiction with significant societal impact, accounting for one of every five deaths. Smoking cessation therapies to help smokers quit are ineffective with a high recidivism rate. With the knowledge that nicotine is the principal addictive compound of cigarettes, we have developed an antismoking vaccine based on the highly immunogenic properties of the hexon protein purified from the serotype 5 adenovirus (Ad) capsid. We hypothesized that an effective antinicotine vaccine could be based on coupling the nicotine hapten AM1 to purified Ad hexon protein. To assess this, AM1 was conjugated to hexon purified from serotype 5 Ad to produce the HexonAM1 vaccine. C57Bl/6 mice were sensitized by 10 daily nicotine administrations (0.5 mg/kg, subcutaneous) to render the mice addicted to nicotine. Control groups were sensitized to phosphate-buffered saline (PBS). The mice were then immunized with HexonAM1 (4 μg, intramuscular) at 0, 3, and 6 weeks. By 6 weeks, the HexonAM1-vaccinated mice had serum antinicotine antibody titers of 1.1×106±7. 6×104. To demonstrate that these high antinicotine titers were sufficient to suppress the effects of nicotine, HexonAM1-vaccinated mice were evaluated for nicotine-induced hypoactive behavior with nicotine challenges (0.5 mg/kg wt) over 5 weeks. In all challenges, the HexonAM1-vaccinated mice behaved similar to PBS-challenged naive mice. These data demonstrate that a vaccine comprised of a nicotine analog coupled to Ad hexon can evoke a high level of antinicotine antibodies sufficient to inhibit nicotine-induced behavior. The HexonAM1 vaccine represents a platform paradigm for vaccines against small molecules.

Original languageEnglish
Pages (from-to)595-603
Number of pages9
JournalHuman Gene Therapy
Volume24
Issue number6
DOIs
Publication statusPublished - 1 Jun 2013
Externally publishedYes

Fingerprint

Nicotine
Adenoviridae
Vaccines
Phosphates
Antibodies
Haptens
Capsid
Smoking Cessation
Tobacco Products
Smoking
Control Groups
Serum

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Rosenberg, J. B., De, B. P., Hicks, M. J., Janda, K. D., Kaminsky, S. M., Worgall, S., & Crystal, R. (2013). Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. Human Gene Therapy, 24(6), 595-603. https://doi.org/10.1089/hum.2012.245

Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. / Rosenberg, Jonathan B.; De, Bishnu P.; Hicks, Martin J.; Janda, Kim D.; Kaminsky, Stephen M.; Worgall, Stefan; Crystal, Ronald.

In: Human Gene Therapy, Vol. 24, No. 6, 01.06.2013, p. 595-603.

Research output: Contribution to journalArticle

Rosenberg, JB, De, BP, Hicks, MJ, Janda, KD, Kaminsky, SM, Worgall, S & Crystal, R 2013, 'Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine', Human Gene Therapy, vol. 24, no. 6, pp. 595-603. https://doi.org/10.1089/hum.2012.245
Rosenberg JB, De BP, Hicks MJ, Janda KD, Kaminsky SM, Worgall S et al. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. Human Gene Therapy. 2013 Jun 1;24(6):595-603. https://doi.org/10.1089/hum.2012.245
Rosenberg, Jonathan B. ; De, Bishnu P. ; Hicks, Martin J. ; Janda, Kim D. ; Kaminsky, Stephen M. ; Worgall, Stefan ; Crystal, Ronald. / Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. In: Human Gene Therapy. 2013 ; Vol. 24, No. 6. pp. 595-603.
@article{b07d9dceaa6043dfb8d6de1dd6e249d6,
title = "Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine",
abstract = "Despite antismoking campaigns, cigarette smoking remains a pervasive addiction with significant societal impact, accounting for one of every five deaths. Smoking cessation therapies to help smokers quit are ineffective with a high recidivism rate. With the knowledge that nicotine is the principal addictive compound of cigarettes, we have developed an antismoking vaccine based on the highly immunogenic properties of the hexon protein purified from the serotype 5 adenovirus (Ad) capsid. We hypothesized that an effective antinicotine vaccine could be based on coupling the nicotine hapten AM1 to purified Ad hexon protein. To assess this, AM1 was conjugated to hexon purified from serotype 5 Ad to produce the HexonAM1 vaccine. C57Bl/6 mice were sensitized by 10 daily nicotine administrations (0.5 mg/kg, subcutaneous) to render the mice addicted to nicotine. Control groups were sensitized to phosphate-buffered saline (PBS). The mice were then immunized with HexonAM1 (4 μg, intramuscular) at 0, 3, and 6 weeks. By 6 weeks, the HexonAM1-vaccinated mice had serum antinicotine antibody titers of 1.1×106±7. 6×104. To demonstrate that these high antinicotine titers were sufficient to suppress the effects of nicotine, HexonAM1-vaccinated mice were evaluated for nicotine-induced hypoactive behavior with nicotine challenges (0.5 mg/kg wt) over 5 weeks. In all challenges, the HexonAM1-vaccinated mice behaved similar to PBS-challenged naive mice. These data demonstrate that a vaccine comprised of a nicotine analog coupled to Ad hexon can evoke a high level of antinicotine antibodies sufficient to inhibit nicotine-induced behavior. The HexonAM1 vaccine represents a platform paradigm for vaccines against small molecules.",
author = "Rosenberg, {Jonathan B.} and De, {Bishnu P.} and Hicks, {Martin J.} and Janda, {Kim D.} and Kaminsky, {Stephen M.} and Stefan Worgall and Ronald Crystal",
year = "2013",
month = "6",
day = "1",
doi = "10.1089/hum.2012.245",
language = "English",
volume = "24",
pages = "595--603",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine

AU - Rosenberg, Jonathan B.

AU - De, Bishnu P.

AU - Hicks, Martin J.

AU - Janda, Kim D.

AU - Kaminsky, Stephen M.

AU - Worgall, Stefan

AU - Crystal, Ronald

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Despite antismoking campaigns, cigarette smoking remains a pervasive addiction with significant societal impact, accounting for one of every five deaths. Smoking cessation therapies to help smokers quit are ineffective with a high recidivism rate. With the knowledge that nicotine is the principal addictive compound of cigarettes, we have developed an antismoking vaccine based on the highly immunogenic properties of the hexon protein purified from the serotype 5 adenovirus (Ad) capsid. We hypothesized that an effective antinicotine vaccine could be based on coupling the nicotine hapten AM1 to purified Ad hexon protein. To assess this, AM1 was conjugated to hexon purified from serotype 5 Ad to produce the HexonAM1 vaccine. C57Bl/6 mice were sensitized by 10 daily nicotine administrations (0.5 mg/kg, subcutaneous) to render the mice addicted to nicotine. Control groups were sensitized to phosphate-buffered saline (PBS). The mice were then immunized with HexonAM1 (4 μg, intramuscular) at 0, 3, and 6 weeks. By 6 weeks, the HexonAM1-vaccinated mice had serum antinicotine antibody titers of 1.1×106±7. 6×104. To demonstrate that these high antinicotine titers were sufficient to suppress the effects of nicotine, HexonAM1-vaccinated mice were evaluated for nicotine-induced hypoactive behavior with nicotine challenges (0.5 mg/kg wt) over 5 weeks. In all challenges, the HexonAM1-vaccinated mice behaved similar to PBS-challenged naive mice. These data demonstrate that a vaccine comprised of a nicotine analog coupled to Ad hexon can evoke a high level of antinicotine antibodies sufficient to inhibit nicotine-induced behavior. The HexonAM1 vaccine represents a platform paradigm for vaccines against small molecules.

AB - Despite antismoking campaigns, cigarette smoking remains a pervasive addiction with significant societal impact, accounting for one of every five deaths. Smoking cessation therapies to help smokers quit are ineffective with a high recidivism rate. With the knowledge that nicotine is the principal addictive compound of cigarettes, we have developed an antismoking vaccine based on the highly immunogenic properties of the hexon protein purified from the serotype 5 adenovirus (Ad) capsid. We hypothesized that an effective antinicotine vaccine could be based on coupling the nicotine hapten AM1 to purified Ad hexon protein. To assess this, AM1 was conjugated to hexon purified from serotype 5 Ad to produce the HexonAM1 vaccine. C57Bl/6 mice were sensitized by 10 daily nicotine administrations (0.5 mg/kg, subcutaneous) to render the mice addicted to nicotine. Control groups were sensitized to phosphate-buffered saline (PBS). The mice were then immunized with HexonAM1 (4 μg, intramuscular) at 0, 3, and 6 weeks. By 6 weeks, the HexonAM1-vaccinated mice had serum antinicotine antibody titers of 1.1×106±7. 6×104. To demonstrate that these high antinicotine titers were sufficient to suppress the effects of nicotine, HexonAM1-vaccinated mice were evaluated for nicotine-induced hypoactive behavior with nicotine challenges (0.5 mg/kg wt) over 5 weeks. In all challenges, the HexonAM1-vaccinated mice behaved similar to PBS-challenged naive mice. These data demonstrate that a vaccine comprised of a nicotine analog coupled to Ad hexon can evoke a high level of antinicotine antibodies sufficient to inhibit nicotine-induced behavior. The HexonAM1 vaccine represents a platform paradigm for vaccines against small molecules.

UR - http://www.scopus.com/inward/record.url?scp=84879171193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879171193&partnerID=8YFLogxK

U2 - 10.1089/hum.2012.245

DO - 10.1089/hum.2012.245

M3 - Article

VL - 24

SP - 595

EP - 603

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 6

ER -